The AFFIRM trial tests the safety and clinical feasibility of MR-guided hypofractionated focal boost radiotherapy for patients with locally advanced prostate cancer. External beam radiotherapy combined with androgen deprivation therapy is considered as the treatment of choice for patients with locally advanced non-metastatic prostate cancer with seminal vesicle invasion.The long-term results of the multicentre phase III study (FLAME trial) showed that addition of an isotoxic focal boost to the intraprostatic lesion improves biochemical disease free survival in intermediate to high-risk patients without impacting toxicity and quality of life. This focal boost strategy is now proven for a conventional fractionation scheme (35 fractions). The current trend in radiotherapy for prostate cancer is (extreme) hypofractionation, reducing the number of fractions. For locally advanced prostate cancer, however, the data on extreme hypofractionation are scarce.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
95
External beam MR-guided (MR-linac) radiotherapy to the prostate and seminal vesicles of 5x7Gy (once weekly) with an isotoxic integrated focal boost up to 50Gy to the intraprostatic tumor as visible on multiparametric MRI.
Radboudumc
Nijmegen, Gelderland, Netherlands
Netherlands Cancer Institute
Amsterdam, North Holland, Netherlands
Acute gastrointestinal and genitourinary toxicity
Acute gastrointestinal (GI) and genitourinary (GU) Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0). Acute toxicity is defined as toxicity occurring within 90 days after the first radiation treatment (e.g. 60 days after completion of the radiation treatment).
Time frame: 90 days after start of treatment
Late GI and GU toxicity (CTCAE v5.0)
assessed between 90 days and up to 5 years after the first radiation treatment
Time frame: from 90 days after start of treatment up to 5 years
Quality of life
using the EORTC QLQ-C30 questionnaires
Time frame: from baseline up to 5 years after completion of treatment
Quality of life
using the EORTC QLQ-PR25 questionnaires
Time frame: from baseline up to 5 years after completion of treatment
Biochemical disease free survival
measuring the PSA concentration using the Phoenix definition for biochemical recurrence
Time frame: up to 5 years after completion of treatment
Overall survival
Time frame: up to 5 years after completion of treatment
Prostate cancer specific survival
Time frame: up to 5 years after completion of treatment
Distant metastasis free survival
Time frame: up to 5 years after completion of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.